208 related articles for article (PubMed ID: 15962635)
1. Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
Kietpeerakool C; Suprasert P; Srisomboon J
J Med Assoc Thai; 2005 Mar; 88(3):301-6. PubMed ID: 15962635
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
3. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Matulonis UA; Krag KJ; Krasner CN; Atkinson T; Horowitz NS; Lee H; Penson RT
Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
5. [Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].
Nagao S; Okimoto N; Hongo A; Mizutani Y; Kodama J; Yoshinouchi M; Hiramatsu Y; Kudo T
Gan To Kagaku Ryoho; 2003 Feb; 30(2):243-9. PubMed ID: 12610873
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
8. [Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
Kumagai M; Fujii T; Komatsu M; Kusuda T; Takehara K; Shinkou S; Naitou H
Gan To Kagaku Ryoho; 2004 Apr; 31(4):555-9. PubMed ID: 15114699
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
10. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
Rose PG; Smrekar M; Fusco N
Gynecol Oncol; 2005 Feb; 96(2):296-300. PubMed ID: 15661211
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
[TBL] [Abstract][Full Text] [Related]
14. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
15. A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
Vapattanawong P
J Med Assoc Thai; 2006 Sep; 89(9):1357-61. PubMed ID: 17100369
[TBL] [Abstract][Full Text] [Related]
16. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
17. Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer.
Kietpeerakool C; Tiyayon J; Suprasert P; Kanjanavanit R; Srisomboon J
J Med Assoc Thai; 2006 Nov; 89(11):1805-10. PubMed ID: 17205858
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
19. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer.
Dinniwell R; Lock M; Pintilie M; Fyles A; Laframboise S; Depetrillo D; Levin W; Manchul L; Murphy J; Oza A; Rosen B; Sturgeon J; Milosevic M
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):104-10. PubMed ID: 15850909
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Spriggs DR; Brady MF; Vaccarello L; Clarke-Pearson DL; Burger RA; Mannel R; Boggess JF; Lee RB; Hanly M
J Clin Oncol; 2007 Oct; 25(28):4466-71. PubMed ID: 17906207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
